15 Signs That Confirm You’re Definitely a Spoonie

A “spoonie” is a term used by people with chronic illnesses. It stems from lupus blogger Christine Miserandino who explained her lack of energy using spoons. How do you know if you’re a spoonie? We’ve scoured the Internet for some examples of what it’s like to be…

An imbalance between production and degradation of protein in the central nervous system may contribute to amyotrophic lateral sclerosis (ALS), researchers at England’s University of Sheffield suggest. Their study, “Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?,” appeared in the journal Frontiers in Molecular Neuroscience. It reviewed available data showing that disturbances in…

HVH Precision Analytics presented findings of its big data analysis for earlier diagnosis of ALS (amyotrophic lateral sclerosis) to help clinicians treat patients sooner and allow patients to possibly enroll in clinical trials. HVH’s poster presentation, titled “Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS),” took place at…

In this video, Dr. Simon Freilich gives an overview of the main type of motor neuron disease: amyotrophic lateral sclerosis (ALS). MORE: 16 fast facts about amyotrophic lateral sclerosis Dr. Freilich explains that ALS accounts for around 85 percent of motor neuron disease cases. The…

One of the most frustrating symptoms of living with a chronic illness is brain fog. There are medications to treat many symptoms of chronic diseases, but sadly there isn’t yet a pill that takes away brain fog. However, there are ways to deal with it so patients can minimize its effects and…

Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In lab studies with mice, the therapy restored resident immune cells of the central nervous system, which could indicate…

Data from the open-label extension trial of Radicava (edaravone) in patients with amyotrophic lateral sclerosis (ALS) demonstrated that the treatment continued to provide benefits after 48 weeks of treatment. These findings — presented by researchers from MT Pharma America at the May 18-20 European Network for the Cure…

As part of ALS Awareness Month, we’re looking at some of the research into ALS and which populations are more likely to develop the disease. Over the years, researchers have focused on the connection between firefighters and various diseases, including cancer and heart disease, but recent studies have shown that firefighters are more…

French biotech company AB Science presented the results of the Phase 3 clinical trial for its lead compound masitinib, which showed effectiveness in improving the functioning of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The randomized, double-blind clinical trial (NCT02588677) compared the efficacy and…

Mutations in the UBQLN4 gene may contribute to the development of amyotrophic lateral sclerosis (ALS), according to recent research. The study, “A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis,” was published in the journal eLife. Over the years, researchers have identified numerous genes linked to ALS, but the list…